BioCardia Announces the Appointment of Two New Board Members
October 02 2019 - 8:00AM
BioCardia (Nasdaq: BCDA), a leader in the development of
comprehensive solutions for cardiovascular regenerative therapies,
today announced the appointment of experienced CEOs Jim Allen and
Andrew Blank to its Board of Directors, effective October 1, 2019.
Mr. Allen is Chief Executive Officer and President
of Sea Star, Inc., a real estate development company, and has
served in that capacity since he founded the company in February
1989. He has founded multiple companies from concept to full
operation involving the development of various technologies,
patents, manufacturing processes, and sales, distribution and
maintenance programs. Six of his ventures have resulted in sales to
publicly-traded companies. He is a named inventor on 29 issued and
pending patents. Mr. Allen studied business at Troy University and
Auburn University at Montgomery.
Mr. Blank is President of National Brands, Inc., an
investment group that was the largest Anheuser-Busch beer
distributor in the world prior to divestiture of those operations,
and has served in that capacity since March 1993. He also
currently serves as President of three other companies: WareITis
Technologies, developer of the foremost enterprise level content
management software suite called Records Studio; Archive America,
the country’s largest family-owned document storage firm; and
Seaboard Warehouse Terminals, a provider of nationwide third-party
logistics services. Mr. Blank holds a bachelor’s degree in
business from the University of Miami.
“We will benefit from new blood on the Board and I
look forward to working with our new Directors who are active
investors in the company and excited by its prospects,” said
BioCardia CEO Peter Altman. “Jim and Andrew join BioCardia at an
exciting time as we enroll our pivotal CardiAMP Heart Failure
Trial, explore new indications, and enhance our delivery systems.
They are both experienced at leading companies to success and we
expect to draw upon their experience and insights as we drive our
therapies and products forward.”
These new board members replace two board members
who have recently retired from the Company's Board, Thomas
Quertermous, M.D. and Allan R. Tessler.
“I want to thank Tom and Allan for their service to
BioCardia and expect them to benefit from our future success as
continuing shareholders,” said Altman.
About BioCardia®BioCardia,
Inc., headquartered in San Carlos, California, is developing
regenerative biologic therapies to treat cardiovascular disease.
CardiAMP™ and CardiALLO™ cell therapies are the Company’s
biotherapeutic product candidates in clinical development. The
Company's current products include the Helix™ Biotherapeutic
Delivery System and the Morph® steerable guide and sheath catheter
portfolio, including the new AVANCE™ Steerable Introducer family.
BioCardia also partners with other biotherapeutic companies to
provide its Helix systems and clinical support to their programs
studying therapies for the treatment of heart failure, chronic
myocardial ischemia and acute myocardial infarction.
Forward-Looking Statements: This
press release contains forward-looking statements that are subject
to many risks and uncertainties. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies, regulatory approvals, unexpected
expenditures, the ability to raise the additional funding needed to
continue to pursue BioCardia’s business and product development
plans and overall market conditions. These forward-looking
statements are made as of the date of this press release, and
BioCardia assumes no obligation to update the forward-looking
statements.
We may use terms such as “believes,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify
these forward-looking statements. Although we believe that we have
a reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results, and
the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
press release. As a result of these factors, we cannot assure you
that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could materially
affect actual results can be found in BioCardia’s
Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2019, including under the caption titled
“Risk Factors.” BioCardia expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
INVESTOR CONTACT: David McClung,
Chief Financial Officer investors@BioCardia.com, (650) 226-0120
MEDIA CONTACT:Michelle McAdam,
Chronic Communications, Inc.michelle@chronic-comm.com, (310)
545-6654
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Apr 2023 to Apr 2024